The sales of a pharmaceutical drug are most often directly dependent on the actual availability at the point of sale at the time of the consumer’s request. Manufacturers tend to try to make sure that their products have the highest numeric distribution, although it is bound to fluctuate. While the distribution of certain products usually increases at the launch, the distribution can sometimes drop due to competition or supply interruptions.

In January–April 2024, 14.3 billion rubles worth of veterinary drugs were sold on the Russian veterinary retail market (retail prices, VAT included), up 15.6% from the same period in 2023. In physical terms, 85.6 million minimum dosage units (MDU) were sold, up 12% from January–April 2023. Online sales contributed to the high growth rates the most—they went up 73.4% in monetary terms and 50.8% in physical terms. The growth rates of the offline channel are only 5.4% and 6.9%.

In 2023, veterinary drugs on the Russian retail market (e-com included) went up in price 26.6% from 2022. The fastest price growth rates were seen in early 2023; as a result of the devaluation of the ruble and the subsequent correction of prices for imported goods on the Russian market, inflation surged in June–August 2023. By the end of the year, the prices had stabilized, dropping to a year-low. January and February 2024, however, saw an upward trend (26.4% and 28.6%, respectively), which peaked in March 2024 with 44.9%, and continued in April 2024 with 44.3%. In January–April 2024, the price index was 38.6%.

In 2023, Russia manufactured 21.04 billion doses of veterinary vaccines and anatoxins, up 27.5% from 2022. Manufacture fell just once in the past 5 years—by 1.1% in 2020. Since 2022, however, manufacture has been growing at a double-digit rate. In Q1 2024, 7.02 billion doses were manufactured against 4 billion in the same period in 2023—a record-high increase of 68.3%.